Synthesis and cardioprotective effect of a novel anti-ischemic / reperfused injury compound

The aim of present study is to investigate the cardioprotective effect of a new compound acetyl ferulaic isosorbide (AFI), composed of ferulaic acid (FA) and isosorbide mononitrate (ISMN) by esterification in myocardial ischemia/reperfusion (MI/R).  Male Sprague-Dawley rats, subjected to 30 minutes of myocardial ischemia and 3 hours of reperfusion, randomly received one of the following treatments separately: SHAM, I/R (MI/R + solvent), SF (MI/R+SF, 40 mg·kg^-1, ig), ISMN (MI/R + ISMN, 30 mg·kg^-1, ig), SF + ISMN (MI/R + SF + ISMN, 40 mg·kg^-1 + 30 mg·kg^-1, ig) and AFI (MI/R + AFI, 10 mg·kg^-1, ig).  Left ventricle developed pressures (LVDP) and the maximal first derivative of developed pressure (± dP/dt_max) were monitored throughout the   experiments.  Myocardial infarction size, serum creatine kinase (CK) activity, lactate dehydrogenase (LDH)  activity, superoxide dismutase (SOD) activity, hydrogen peroxide (H₂O₂), malondialdehyde (MDA) and nitric oxide (NO) production were determined at the end of reperfusion.  Compared with SF, ISMN or SF + ISMN treatment groups, AFI treatment decreased infarction size (n = 8, P < 0.01), improved cardiac function as     evidenced by increased LVDP and ± dP/dt_max (n = 8, P < 0.05), increased serum SOD activity, reduced serum CK and LDH activities, H₂O₂ and MDA production (n = 8, P < 0.05).  The new compound AFI showed a stronger cardioprotective effect against MI/R injury than SF, ISMN or their combined administration did.